| 保荐人名称：中国国际金融股份有限公司 | 被保荐公司简称：瑞迈特 | | --- | --- | | 保荐代表人姓名：陈婷婷 | 联系电话：010-65051166 | | 保荐代表人姓名：杨 桐 | 联系电话：010-65051166 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0 次 | | 2.督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不 | | | 限于防止关联方占用公司资源的制度、募集资金管 | 是 | | 理制度、内控制度、内部审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 次（每月一次） 6 | | （2）公司募集资金项目进展是否与信息披露文件 | 是 | | 一致 | | | 4.公司治理督导情况 | | | （1）列席公司股东大会次数 | 未列席，已事前审 ...

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于北京瑞迈特医疗科技股份有限公司 2025 年第二次临时股东会的 法律意见书 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》 （以下简称"《股东会规则》"）、《律师事务所从事证券法律业务管理办法》 （以下简称"《证券法律业务管理办法》"）、《律师事务所证券法律业务执业 规则（试行）》（以下简称"《证券法律业务执业规则》"）等相关法律、行政 法规、规章、规范性文件及《北京瑞迈特医疗科技股份有限公司章程》（以下简 称"《公司章程》"）的规定，就本次会议的召集与召开程序、召集人资格、出 席会议人员资格、会议表决程序及表决结果等事宜，出具本法律意见书。 对本法律意见书的出具，本所律师特作如下声明： 1．本所律师仅就本次会议的召集与召开程序、召集人和出席现场会议人员 资格、会议表决程序及表决结果的合法性发表意见，不对本次会议所审议的议案 内容及该 ...

2025年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1. 本次股东会未出现否决议案的情形； 2. 本次股东会未涉及变更前次股东会已通过的决议的情形。 一、会议召开和出席情况 证券代码：301367 证券简称：瑞迈特 公告编号：2025-057 北京瑞迈特医疗科技股份有限公司 （一）会议召开情况 1、会议召开的日期、时间： （1）现场会议时间：2025 年 9 月 16 日（星期二）下午 14:00； （2）网络投票时间：2025 年 9 月 16 日，其中通过深交所交易系统进行网 络投票的具体时间为：2025 年 9 月 16 日上午 09:15-09:25，09:30-11:30，下午 13:00-15:00；通过互联网系统进行投票的具体时间为：2025 年 9 月 16 日上午 9:15 至下午 15:00 期间的任意时间。 2、会议的召开方式：本次股东会采用现场表决与网络投票相结合的方式召 开。 3、会议地点：北京市丰台区丽泽路 16 号院 4 号楼北京汇亚大厦 17 层 10 号 4、会议的召集人：公司第三届 ...

Group 1 - The company announced a change in its sponsor representatives, with Yang Tong and Chen Tingting appointed as the new continuous supervision sponsor representatives [2] - The continuous supervision period is set to end on December 31, 2025 [2]

证券代码：301367 证券简称：瑞迈特 公告编号：2025-056 北京瑞迈特医疗科技股份有限公司 关于变更持续督导保荐代表人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北京瑞迈特医疗科技股份有限公司（以下简称"公司"）于近日收到保荐机 构中国国际金融股份有限公司（以下简称"中金公司"）出具的《关于变更北京 瑞迈特医疗科技股份有限公司持续督导保荐代表人的函》。 中金公司作为公司首次公开发行股票并在创业板上市的保荐机构及持续督导 机构，自瑞迈特首发上市日（2022 年 11 月 1日）起至 2025 年 12月 31日期间，承 担持续督导责任。中金公司原委派的陈婷婷女士、高广伟先生担任公司持续督导 保荐代表人，现因原保荐代表人高广伟先生工作变动，无法继续负责公司持续督 导保荐工作。为保证公司持续督导工作有序进行，中金公司现委派杨桐先生接替 高广伟先生担任公司的持续督导保荐代表人，继续履行相关职责。 本次保荐代表人更换后，公司的持续督导保荐代表人为杨桐先生（简历详见 附件）和陈婷婷女士，持续督导期截至 2025年 12月 31日。 公司董事会对高广伟 ...

Investment Rating - The report maintains a "Buy" rating for the company [7] Core Views - The company has shown continuous improvement in revenue quarter-on-quarter, with significant growth in the US and European markets. The inventory destocking cycle in the US has ended, and the European market has begun to enter mainstream medical insurance markets. Domestic market adjustments are showing initial results, leading to dual growth in revenue and profit in Q2 2025 [2][4] - The company’s new noise-reducing cotton ventilator has been launched in the US market, with expectations for increased volume in the second half of the year. The company is deepening its localization strategy overseas, enhancing its global competitiveness [2][3] Financial Performance - In H1 2025, the company achieved operating revenue of 544 million yuan, a year-on-year increase of 42.30%, and a net profit attributable to the parent company of 131 million yuan, also up 42.19%. In Q2 2025, revenue reached 279 million yuan, growing 46.54% year-on-year, with a net profit of 59.41 million yuan, up 39.92% [1][4] - The company’s gross margin in Q2 2025 was 54.64%, an increase of 2.98 percentage points year-on-year. The sales expense ratio decreased by 1.82 percentage points to 12.75%, while the management expense ratio fell by 3.20 percentage points to 6.65% [2] Business Segments - The company’s main business lines showed strong growth in H1 2025: - Home respiratory therapy products generated revenue of 349 million yuan, up 51.49% year-on-year, with a gross margin of 45.02% - Consumables generated revenue of 178 million yuan, up 30.26%, with a gross margin of 65.83% - Medical products generated revenue of 16.56 million yuan, up 12.96%, with a gross margin of 55.77% [3] - Domestic revenue reached 191 million yuan in H1 2025, a year-on-year increase of 16.87%, while overseas revenue was 353 million yuan, up 61.33% [4] Market Outlook - The company is expected to see revenue growth of 27.7%, 22.6%, and 21.2% for the years 2025, 2026, and 2027, respectively, with net profits projected to grow by 76.0%, 31.5%, and 23.0% in the same years [4]

Core Viewpoint - The company, 瑞迈特, has experienced fluctuations in its stock price and trading volume, with a notable increase in revenue and profit year-over-year, indicating strong business performance in the medical device sector [1][2]. Group 1: Stock Performance - On September 9, 瑞迈特's stock price decreased by 2.01%, trading at 91.27 yuan per share, with a total market capitalization of 8.178 billion yuan [1]. - The stock has increased by 45.79% year-to-date, with a 2.21% rise over the last five trading days, a 6.65% decline over the last 20 days, and a 12.51% increase over the last 60 days [1]. Group 2: Financial Performance - For the first half of 2025, 瑞迈特 reported a revenue of 544 million yuan, representing a year-on-year growth of 42.30%, and a net profit attributable to shareholders of 131 million yuan, also up by 42.19% [2]. - The company has distributed a total of 228 million yuan in dividends since its A-share listing [3]. Group 3: Business Overview - 瑞迈特 specializes in the research, production, and sales of medical devices and consumables in the respiratory health sector, primarily targeting patients with obstructive sleep apnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD) [1]. - The revenue composition of the company includes 64.19% from home respiratory therapy products, 32.67% from consumables, 3.05% from medical products, and 0.10% from other sources [1]. Group 4: Shareholder Information - As of June 30, 2025, 瑞迈特 had 6,850 shareholders, a decrease of 24.87% from the previous period, with an average of 8,251 circulating shares per shareholder, an increase of 33.11% [2]. - The Hong Kong Central Clearing Limited has exited the list of the top ten circulating shareholders [3].

Investment Rating - The investment rating for the company is "Buy" and is maintained [8]. Core Insights - The company's performance met expectations, with a significant recovery in overseas growth. In the first half of 2025, the company achieved revenue of 544 million yuan, a year-on-year increase of 42.30%. The net profit attributable to the parent company was 131 million yuan, also up 42.19% year-on-year [2][6]. - The overseas revenue for the first half of 2025 reached 353 million yuan, reflecting a year-on-year growth of 61.33%. In the second quarter alone, revenue was 279 million yuan, with overseas business revenue at 183 million yuan, marking a year-on-year increase of 95.97% and a quarter-on-quarter increase of 7.97% [2][11]. - The company is focusing on research and development, with a new noise-reducing cotton respirator expected to launch in the U.S. market in the second half of 2025 [11]. Summary by Sections Financial Performance - In the first half of 2025, the company reported total revenue of 544 million yuan, with a net profit of 131 million yuan and a non-recurring net profit of 99 million yuan, showing year-on-year increases of 42.30%, 42.19%, and 49.34% respectively. In the second quarter, revenue was 279 million yuan, with a net profit of 59 million yuan, reflecting year-on-year growth of 46.54% and 39.92% respectively [6][11]. Overseas Market Growth - The U.S. market saw a revenue increase of 252.89% year-on-year, while Europe experienced a growth of 63.95%. This growth is attributed to the end of the inventory destocking cycle in the U.S. respiratory market and the completion of cloud platform construction in Europe [2][11]. Domestic Market Strategy - Domestic revenue reached 191 million yuan in the first half of 2025, a year-on-year increase of 16.87%. The company is transitioning from a distribution model to direct sales, which is expected to drive further growth [11]. Research and Development - The company has established a comprehensive R&D system, with 266 overseas patents, including 45 in the U.S. and 38 in Europe. The new noise-reducing cotton respirator is anticipated to begin volume sales in the U.S. market in the latter half of 2025 [11]. Profit Forecast - The company is projected to be a global leader in home medical devices, with net profits expected to reach 255 million yuan, 332 million yuan, and 433 million yuan for 2025, 2026, and 2027 respectively, corresponding to P/E ratios of 31, 23, and 18 [11].

Company Overview - The company, established in 2001, specializes in providing comprehensive treatment solutions for OSA and COPD patients, covering diagnosis, treatment, and chronic disease management [2] - It is a leading domestic manufacturer of non-invasive ventilators and masks, being the first domestic company to receive FDA certification for its non-invasive ventilator products [2] - The company has a well-rounded product line that includes home non-invasive ventilators, masks, sleep monitors, high-flow humidified oxygen therapy devices, and oxygen concentrators, and it offers chronic disease management services [2] Research and Development - The company maintains significant R&D investments, holding 666 valid domestic patents as of June 30, 2025, including 116 invention patents and 404 utility model patents [3] - It has also secured 266 overseas patents, including 45 in the United States and 38 in Europe [3] Financial Performance - For the first half of 2025, the company reported revenue of 544 million yuan, a year-on-year increase of 42.3%, and a net profit of 131 million yuan, also up 42.19% [11] - In Q2 2025, revenue reached 279 million yuan, reflecting a 46.54% year-on-year growth, with a net profit of 59.41 million yuan, up 39.92% [11] Profitability - The company's gross margin improved due to effective cost control and a higher proportion of sales from consumables, which have a higher gross margin [4] - The gross margin for the company was reported at 52.17% [11] Market Expansion - The company experienced significant growth in overseas markets, particularly in the United States, where revenue increased by 252.89% year-on-year [5] - Future plans include launching a new noise-reducing ventilator in the U.S. market and expanding into the European market with products entering mainstream insurance markets [6] Domestic Market Strategy - The company is transitioning smoothly to online channels while maintaining stable operations in the domestic market [9] - It plans to implement a multi-model product sales strategy for online self-operated channels and differentiate products for offline channels [9] Consumables Business - In the first half of 2025, consumables accounted for approximately 30% of the company's revenue, with expectations for continued growth driven by increased awareness and market penetration of ventilators [10]

Group 1 - The core viewpoint of the article highlights that the growth of 瑞迈特 (301367.SZ) is significantly driven by the American region, which has shown a remarkable revenue increase [1] - In the first half of the year, the revenue from the American region increased by 252.89% year-on-year [1]